Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDIA6 | Q15084 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 12/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575651 | 1.00 | PDIA6 (0.67) | PDIA6PKMSMN1; SMN2L3MBTL1CA2 | |
| SCHEMBL8295570 | 0.85 | ALDH1A1 (0.51) | PDIA6SMN1; SMN2L3MBTL1CA2CA1 | |
| SCHEMBL4203848 | 0.84 | PKM (0.58) | PDIA6PKMSMN1; SMN2L3MBTL1FFAR4 | |
| SCHEMBL31235134 | 0.82 | CA2 (0.51) | PDIA6PKML3MBTL1CA2CA1 | |
| SCHEMBL16936936 | 0.82 | CA2 (0.51) | PDIA6PKML3MBTL1CA2CA1 | |
| SCHEMBL12036349 | 0.82 | SMN1; SMN2 (0.57) | PDIA6PKMSMN1; SMN2L3MBTL1FFAR4 | |
| SCHEMBL1817467 | 0.81 | PKM (0.55) | PDIA6PKMSMN1; SMN2L3MBTL1CA2 | |
| SCHEMBL1522779 | 0.81 | ALDH1A1 (0.53) | PDIA6PKMSMN1; SMN2CA2CA1 | |
| SCHEMBL2183386 | 0.81 | PKM (0.55) | PKML3MBTL1CA2CA1CA9 | |
| SCHEMBL29551296 | 0.81 | PKM (0.55) | PKML3MBTL1CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111362857-A | Compound with indoline skeleton, preparation method and medical application thereof | 中国药科大学 | 2020-07-03 | — | — | CN | claimed |
| WO-2011149827-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-12-01 | — | — | WO | claimed |
| CN-111362857-B | Compound with indoline skeleton, preparation method and medical application thereof | 中国药科大学 | 2023-02-28 | — | — | CN | disclosed |
| US-11186566-B2 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200283405-A1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2020-09-10 | — | — | US | disclosed |
| CN-111362857-A | Compound with indoline skeleton, preparation method and medical application thereof | 中国药科大学 | 2020-07-03 | — | — | CN | disclosed |
| WO-2011149827-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011056739-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283405-A1 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A4, ABCB11 | PDIA6 1399/4885PKM 1762/4885SMN1; SMN2 4741/4885 |
| US-11186566-B2 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SLC26A4, ABCB11 | PDIA6 1399/4885PKM 1762/4885SMN1; SMN2 4741/4885 |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | PDIA6 1774/4885PKM 456/4885SMN1; SMN2 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.